ClinicalTrials.gg
CompletedNCT02982707Updated Nov 14, 2018

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

A Phase 1 interventional study of BMS-986177 in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
13th of 19
26 · median 42
Started
2018
the only one that year
Phase 1
13 of 19
none open now
Registered
12th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 13th largest by enrollment, is the only one that started in 2018, is one of 13 in phase 1, and was the 12th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

A single oral dose of BMS-986177 administered to subjects of mild hepatic impairment, moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and tolerability in these subjects

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women not of (WNOCBP) and males. Women must have documented proof they are not of childbearing potential
  • of 20.0 to 38.0 kg/m2, inclusive
  • Hepatic subjects classified as mild (Class A) or Child-Pugh moderate (Class B) who have had no significant change to disease status in past 6 months and are on stable treatment regimen
  • Healthy subjects must not have deviations from normal in medical history, physical exam, ECGs, vital signs or clinical lab values

Exclusion criteria

Exclusion Criteria:

  • Evidence of coagulopathy, prolonged or unexplained bleeding, or frequent unexplained bruising or thrombus formation
  • Use of , nonsteroidal anti-inflammatory compounds, aspirin or other antiplatelet agents or anticoagulants within 2 weeks of dosing
  • Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse within the last 6 months
  • Subjects must not have a current or recent (within 3 months) GI disease that increases participant risk of GI bleeding or interferes with absorption of the study drug

Other protocol defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Mild Hepatic Subjects

    Subjects are given a single dose of BMS-986177

    Drug: BMS-986177

  • Experimental
    Moderate Hepatic Subjects

    Subjects are given a single dose of BMS-986177

    Drug: BMS-986177

  • Experimental
    Healthy Match Subjects

    Subjects are given a single dose of BMS-986177

    Drug: BMS-986177

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986177

    Time frame: Up to 5 days

  2. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-987177

    Time frame: Up to 5 days

  3. Area under the plasma concentration-time curve from time zero to the time the last quantifiable concentration (AUC(0-T)) of BMS-986177

    Time frame: Up to 5 days

  4. Area under the plasma concentration-time curve from time zero to (AUC(0-72)) of BMS-986177

    Time frame: Up to 5 days

Secondary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation

    Time frame: Screening until 30 days after discontinuation of dosing or subject's participation

  2. Number of participants with clinical laboratory abnormalities

    Time frame: Screening until 30 days after discontinuation of dosing or subject's participation

  3. Number of participants with clinically significant changes in electrical activity of the heart measured by electrocardiogram (ECG)

    Time frame: Screening until 30 days after discontinuation of dosing or subject's participation

  4. Number of participants with vital sign abnormalities

    Time frame: Screening until 30 days after discontinuation of dosing or subject's participation

07

Study locations

3 sites
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Publications

  • Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Chen W, Bello A, Murthy B. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clin Pharmacokinet. 2022 Jun;61(6):857-867. doi: 10.1007/s40262-022-01110-9. Epub 2022 Mar 9. PubMed 35262846 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Sep 2018, 6 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2016
First posted
Dec 5, 2016
StartActual
Mar 1, 2018
Primary completionActual
Sep 28, 2018
CompletionActual
Sep 28, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02982707
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Mar 1, 2018
Primary completion
Sep 28, 2018
Completion
Sep 28, 2018
Last update
Nov 14, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion